SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities who purchased or otherwise acquired Elanco Animal Health Incorporated (NYSE: ELAN) securities between November 7, 2023 and June 26, 2024. Elanco is an animal health company that develops, manufactures, and markets products for pets and farm animals. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. Th ...

SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Elanco Animal Health Incorporated (NYSE: ELAN) securities between November 7, 2023 and June 26, 2024, inclusive (the "Class Period"), have until December 6, 2024 to seek appointment as lead plaintiff of the Elanco Animal class action lawsuit. Captioned Barpar v. Elanco Animal Health Incorporated, No. 24-cv-02912 (D. Md.), the Elanco Animal class action lawsuit charges Elanco Animal and cer ...

NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of Elanco Animal Health Incorporated ("Elanco" or the "Company") (NYSE: ELAN) between November 7, 2023 and June 26, 2024, inclusive (the "Class Period"). For more information, submit a form at Elanco Animal Health Incorporated Shareholder Class Action Lawsuit, email Investor Relations Manager ...

Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) is the first and only canine oral parasiticide to protect against six parasites, including fleas, ticks, heartworms, roundworms, hookwormsii and three different species of tapeworm that other brands skip creating a gap in coverageiii Warming temperatures and changing consumer habits have increased parasite pressure and spread across geographies, bringing with them increased public health risk. Experts recommend monthly tr ...

Itching is one of the top reasons pet owners bring their dog to the veterinarian, and pet owners and veterinarians want more canine dermatology options. Approximately 17 million dogs suffer from allergic skin disease, including atopic dermatitis, food allergies or flea sensitivity2. Among pet owners who say their dog's itch is not under control, 60% say they've tried treating the itch, but nothing works.3 The approval of Zenrelia represents an important advancement in treating itchy dogs suffering from chro ...

GREENFIELD, Ind., Sept. 13, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today provided an update on its relationship with contract manufacturing supplier, TriRx Speke Ltd (TriRx). TriRx today entered into trading administration, a formal insolvency process in the United Kingdom designed to help companies facing severe financial challenges regain stability. Administrators from FTI Consulting LLP have been appointed. Elanco has a long-term supply agreement with TriRx to manufacture sel ...

Product Development and Approval - The company's broad-spectrum parasiticide, Credelio Quattro, is on track for U.S. FDA approval in October 2024, with a targeted launch in the first quarter of 2025 [1] - The FDA has completed its review of all major and minor technical sections for Credelio Quattro, and the final 60-day administrative review is underway [1] - Credelio Quattro is expected to be positively differentiated, with approval sought for indications providing the broadest parasite coverage, including fleas, ticks, heartworms, and other internal parasites like tapeworm [2] - The company is finalizing the manufacturing scale-up to optimize the launch of Credelio Quattro [2] Innovation and Pipeline - The company expects to launch a potential blockbuster product each of the next three quarters in large, fast-growing, or new markets, contributing significantly to its revenue [2] - The company anticipates $600 million to $700 million in innovation sales for 2025 [2] - The company has two potential blockbuster products, Zenrelia and Credelio Quattro, in the final administrative review at the FDA, showcasing its R&D organization's high capacity and ability to deliver consistent high-impact innovation [3] - The company completed the Bovaer review ahead of schedule, further demonstrating its innovation capabilities [3] Company Overview - Elanco Animal Health is a global leader in animal health, dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets [4] - The company has nearly 70 years of animal health heritage and is committed to improving the health of animals, creating value for farmers, pet owners, veterinarians, and society as a whole [4] - Elanco's vision is "Food and Companionship Enriching Life," and it is driven by its Elanco Healthy Purpose™ sustainability pillars to advance the health of animals, people, the planet, and the enterprise [4] FDA Approval Process - The FDA's Center for Veterinary Medicine (CVM) approves and regulates new animal drugs, with the approval process including up to five major technical sections and two minor technical sections [3] - Once all technical sections are complete, the drug sponsor submits the New Animal Drug Application (NADA) for the final administrative review [3]

NEW YORK, Aug. 18, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Why Did Elanco's Stock Drop? Elanco develops products to treat diseases in animals. Two of the most importan ...

Monty Rakusen Background In business since 1954 as a division of Eli Lilly (LLY), Elanco Animal Health (NYSE:EL.AN) was spun off as an independent public company in 2018. In the animal health space, Elanco is second by revenue, behind leader Zoetis (ZTS), with roughly half the revenue of Zoctis, Zoetis was spun off from Pfizer in 2012. Jeffrey N. Simmons has been President and CEO of Elanco since the spinoff from Eli Lilly. On August 1, 2020, Elanco purchased Bayer Animal Health in a deal valued at $6.99 bi ...

NEW YORK, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Why Did Elanco's Stock Drop? Elanco develops products to treat diseases in animals. Two of the most importan ...